The UK life science company COMPASS Pathways receives FDA approval for a clinical trial using psilocybin to treat treatment-resistant depression.
COMPASS Pathways receives US Food and Drug Administration (FDA) approval for clinical trials using psilocybin to treat treatment-resistant depression (TRD). Research sites in the UK, Canada, and the Netherlands have already received regulatory approval. Across all the sites, 215 patients with TRD will take part in the study. Phase III trials will follow if this study is successful.
Psychedelic Science Review is working to bring cutting-edge science in the field of psychedelics to the public in the most accessible, thorough and accurate way possible. Join our communities on Facebook, Twitter, LinkedIn and Instagram and share our content with your network to help us bring scientifically-backed information about psychedelics to the world.
NEW! Shop the PSR Supporter Store to show your support for psychedelic science.